These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Li H; Butler K; Yang L; Yang Z; Teng R Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538 [TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. Cui Q; Robinson L; Elston D; Smaill F; Cohen J; Quan C; McFarland N; Thabane L; McIvor A; Zeidler J; Smieja M AIDS Patient Care STDS; 2012 Jan; 26(1):12-9. PubMed ID: 22007690 [TBL] [Abstract][Full Text] [Related]
30. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Gonzales D; Hajek P; Pliamm L; Nackaerts K; Tseng LJ; McRae TD; Treadow J Clin Pharmacol Ther; 2014 Sep; 96(3):390-6. PubMed ID: 24911368 [TBL] [Abstract][Full Text] [Related]
31. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR; JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370 [TBL] [Abstract][Full Text] [Related]
33. Varenicline (Chantix) for tobacco dependence. Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):66-8. PubMed ID: 16977281 [No Abstract] [Full Text] [Related]
35. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822 [TBL] [Abstract][Full Text] [Related]
37. Practical implementation of varenicline as an aid to smoking cessation in clinical practice. Tonstad S Pneumologia; 2009; 58(3):167-74. PubMed ID: 19817313 [TBL] [Abstract][Full Text] [Related]
38. Smoking cessation with varenicline: a suicidal fatality. Kintz P; Evans J; Villain M; Cirimele V J Anal Toxicol; 2009 Mar; 33(2):118-20. PubMed ID: 19239738 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Jiang J; Tian L; Huang Y; Li Y; Xu L Clin Ther; 2013 Dec; 35(12):1933-45. PubMed ID: 24332196 [TBL] [Abstract][Full Text] [Related]
40. Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. Hajek P; McRobbie H; Myers Smith K; Phillips A; Cornwall D; Dhanji AR JAMA Intern Med; 2015 Feb; 175(2):266-71. PubMed ID: 25545858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]